Cara Therapeutics Inc (CARA) CEO Derek T. Chalmers Sells 20,000 Shares
Cara Therapeutics Inc (NASDAQ:CARA) CEO Derek T. Chalmers sold 20,000 shares of Cara Therapeutics stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $20.64, for a total value of $412,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of Cara Therapeutics traded up $0.31, hitting $21.83, during trading on Thursday, according to MarketBeat.com. 810,518 shares of the company traded hands, compared to its average volume of 1,130,533. Cara Therapeutics Inc has a 1 year low of $11.11 and a 1 year high of $22.29. The stock has a market capitalization of $677.54 million, a PE ratio of -11.74 and a beta of 3.01.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). sell-side analysts forecast that Cara Therapeutics Inc will post -2.17 earnings per share for the current fiscal year.
Several research analysts recently issued reports on the company. ValuEngine upgraded Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. BidaskClub raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 target price (up from $21.00) on shares of Cara Therapeutics in a research note on Thursday, June 28th. HC Wainwright lifted their target price on shares of Cara Therapeutics from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, June 28th. Finally, Needham & Company LLC lifted their target price on shares of Cara Therapeutics from $23.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, June 27th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Cara Therapeutics has a consensus rating of “Buy” and an average target price of $24.75.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.